Specific substrates and products of hsd17b13 as markers of liver disease and biomarkers for liver disease treatment

A method of treatment, comprising:

• administering to a subject a first amount of a 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13) substrate or substrate precursor;
• determining an amount of a reaction product of the HSD17B13 substrate in a sample obtained from the subject, or determining a second amount of the HSD17B13 substrate or substrate precursor in a sample obtained from the subject, after administering the first amount of the HSD17B13 substrate or substrate precursor to the subject;
• determining an HSD17B13 enzyme activity based on the amount of the reaction product, the second amount of the HSD17B13 substrate, or the second amount of the HSD17B13 substrate precursor in the sample;
• and determining an amount of the HSD17B13 inhibitor to administer to the subject based on the HSD17B13 enzyme activity;
• and
• administering or co-administering a first amount of an HSD17B13 inhibitor to the subject with the administration of the first amount of the HSD17B13 substrate or substrate precursor;
• wherein the reaction product comprises an oxidized form of the HSD17B13 substrate;
• the HSD17B13 substrate comprises LTB3, resolvin D1, resolvin E1, protectin DX, maresin 1, 12-HETE, 15-HETE, 13-HODE, 15-HEDE, methyl malonyl coenzyme A, or lauryl coenzyme A, or a salt thereof;
• and
• the HSD17B13 substrate precursor comprises arachidonic acid or linoleic acid, or a salt thereof.